Anti-CGRP monoclonals (galcanezumab/erenumab) for tinnitus with migraine features
Trial details
- Registry identifier: NCT07655440 on ClinicalTrials.gov
- Phase: Phase 2
- Status: Not yet recruiting (verified at ClinicalTrials.gov 2026-09-03)
- Sponsor: Stanford University
- Planned enrollment: 120
- Estimated completion: Not announced
- Country: USA
Why this trial matters
First test of migraine biology as a tinnitus target in the subgroup with migraine features.
Trial statuses are verified against the ClinicalTrials.gov registry by our weekly automated check. A tracked trial is research in progress — inclusion is not a treatment recommendation, and only the study team can determine eligibility.